Latest News From Lumira Ventures

Bardy Diagnostics™ Selected As 1 of 6 Disruptive MedTech Startups for the HealthTech Arkansas Accelerator Program

Jennifer Schram BardyDx, Main Page, Portfolio News, Press Release

Related Article: Bardy Diagnostics™ Selected as 1 of 50 Leading Startups in the 2019 MedTech Innovator Showcase Program SEATTLE, Aug. 9, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that HealthTech …

FDA Grants G1 Therapeutics Breakthrough Therapy Designation in Q2 2019 Corporate and Financial Update

Jennifer Schram G1 Therapeutics, Main Page, Portfolio News, Press Release

Related Article: G1 Therapeutics Provides First Quarter 2019 Corporate and Financial Update RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2019. …

Aurinia Releases Q2 2019 Financial Results

Jennifer Schram Aurinia Pharmaceuticals, Main Page, Portfolio News, Press Release

Related Article: Aurinia Reports First Quarter 2019 Financial Results & Recent Operational Highlights Review condensed consolidated financials here: https://ir.auriniapharma.com/press-releases/detail/153 VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused …

Endotronix Receives conditional IDE approval from the US Food & Drug Administration

Jennifer Schram Endotronix, Main Page, Portfolio News, Press Release

Related Article: Endotronix Receives 13485:2016 certification from the British Standards Institution (BSI) for its Quality Management System LISLE, Ill., Aug. 1, 2019 /PRNewswire/ — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced …

Celgene Exercises Commercial Option for Zymeworks’ Azymetric™ Platform Triggering $7.5MM Milestone Payment

Jennifer Schram Main Page, Portfolio News, Press Release, Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE) — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that its global biopharma partner Celgene Corporation has selected a lead therapeutic candidate in oncology for further development and exercised its option …

Pharmaceutical Industry Executive, Adele M. Gulfo Joins Medexus Pharmaceuticals’ Board of Directors

Jennifer Schram Main Page, Medexus Pharmaceuticals, Portfolio News, Press Release

MONTREAL, June 25, 2019 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), a leading specialty pharmaceutical company with a strong North American commercial platform, announces that Adele M. Gulfo has joined the Company’s Board of Directors, …

Phase 2 Trial Data Demonstrates Longer Survival Rates for Women with Metastatic Breast Cancer Receiving Trilaciclib & Chemotherapy

Jennifer Schram G1 Therapeutics, Main Page, Portfolio News, Press Release

– Detailed data from this trial will be presented at a medical meeting later this year – RESEARCH TRIANGLE PARK, N.C., June 18, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from …

Bardy Diagnostics™ Selected as Winner of the MedTech Breakthrough Award For Best New Diagnostic Technology

Jennifer Schram BardyDx, Main Page, Portfolio News, Press Release

SEATTLE, June 6, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that MedTech Breakthrough, an independent organization that recognizes the top companies and solutions in the global health …

Satsuma Pharmaceuticals Appoints Elisabeth Sandoval to Board of Directors

Jennifer Schram Main Page, Portfolio News, Press Release, Satsuma Pharmaceuticals

Commercial leader brings recent migraine space experience to Satsuma as it advances lead product candidate STS101 into Phase 3 development SOUTH SAN FRANCISCO, Calif., May 29, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”), a Phase 3-stage biopharmaceutical company developing STS101, …